Evidence map›Paper›PMID 38645191›Full record

ArticlemedRxiv : the preprint server for health sciences2024

Factors associated with tuberculosis treatment initiation among bacteriologically negative individuals evaluated for tuberculosis: an individual patient data meta-analysis.

Sun Kim, Melike Hazal Can, Tefera B Agizew, Andrew F Auld, Maria Elvira Balcells, Stephanie Bjerrum, Keertan Dheda, Susan E Dorman, Aliasgar Esmail, Katherine Fielding and 16 more

Open access · greenAbstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors at 17 institutions in 12 countries.

Sun KimDepartment of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA.ORCID 0000-0002-2466-2442
Melike Hazal CanDepartment of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA.ORCID 0000-0001-6810-0356
Tefera B AgizewU.S. Centers for Disease Control and Prevention, Botswana.
Andrew F AuldU.S. Centers for Disease Control and Prevention, Lusaka, Zambia.
Maria Elvira BalcellsInfectious Disease Department, School of Medicine, Pontificia Universidad Católica de Chile.
Stephanie BjerrumDepartment of Clinical Research, University of Southern Denmark, Odense Denmark.
Keertan DhedaCentre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine and UCT Lung Institute, Cape Town, South Africa.
Susan E DormanMedical University of South Carolina, Charleston, SC, USA.
Aliasgar EsmailCentre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine and UCT Lung Institute, Cape Town, South Africa.
Katherine FieldingTB Centre, Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.
Alberto L Garcia-BasteiroISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain.
Colleen F HanrahanEpidemiology Department, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Wakjira KebedeSchool of Medical Laboratory Sciences, Jimma University, Jimma Ethiopia.
Mikashmi KohliFIND, Geneva, Switzerland.
Anne F LuetkemeyerUniversity of California San Francisco, San Francisco, CA, USA.
Carol MitaCountway Library of Medicine, Harvard University, Boston, MA, USA.
Byron W P ReeveDSI-NRF Centre of Excellence for Biomedical Tuberculosis Research and SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa.
Denise Rossato SilvaFaculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Sedona SweeneyFaculty of Public Health and Policy, London School of Hygiene & Tropical Medicine, London, UK.
Grant TheronDSI-NRF Centre of Excellence for Biomedical Tuberculosis Research and SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa.
Anete TrajmanFederal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Anna VassallCentre for Mathematical Modelling of Infectious Diseases, London School of Hygiene & Tropical Medicine, London, UK.
Joshua L WarrenDepartment of Biostatistics, Yale School of Public Health, New Haven, CT, USA.
Marcel YotebiengDivision of General Internal Medicine, Department of Medicine, Albert Einstein College of Medicine, New York City, NY, USA.
Ted CohenDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
Nicolas A MenziesDepartment of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA.ORCID 0000-0002-2571-016X
Harvard University · USLondon School of Hygiene & Tropical Medicine · GBSouth African Medical Research Council · ZAUniversity of Cape Town · ZAYale University · USAlbert Einstein College of Medicine · USCentre for Infectious Disease Research in Zambia · ZMCentro de Investigación Biomédica en Red · ESFIND · CHJimma University · ETJohns Hopkins University · USMedical University of South Carolina · USPontificia Universidad Católica de Chile · CLUniversidade Federal do Rio de Janeiro · BRUniversidade Federal do Rio Grande do Sul · BRUniversity of California, San Francisco · USUniversity of Southern Denmark · DK

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
FEND for TB supplement to accelerate BLINK X developmentU01AI152084 · NIAID · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI ALLAND, DAVID, DORMAN, SUSAN E · 2020 to 2024
$20.0M
NIAID NIH HHS U01 AI152084NIAID NIH HHS UM1 AI068636
6 · The paper itself

Abstract

Background: Globally, over one-third of pulmonary tuberculosis (TB) disease diagnoses are made based on clinical criteria after a negative diagnostic test result. Understanding factors associated with clinicians' decisions to initiate treatment for individuals with negative test results is critical for predicting the potential impact of new diagnostics. Methods: We performed a systematic review and individual patient data meta-analysis using studies conducted between January/2010 and December/2022 (PROSPERO: CRD42022287613). We included trials or cohort studies that enrolled individuals evaluated for TB in routine settings. In these studies participants were evaluated based on clinical examination and routinely-used diagnostics, and were followed for ≥1 week after the initial test result. We used hierarchical Bayesian logistic regression to identify factors associated with treatment initiation following a negative result on an initial bacteriological test (e.g., sputum smear microscopy, Xpert MTB/RIF). Findings: Multiple factors were positively associated with treatment initiation: male sex [adjusted Odds Ratio (aOR) 1.61 (1.31-1.95)], history of prior TB [aOR 1.36 (1.06-1.73)], reported cough [aOR 4.62 (3.42-6.27)], reported night sweats [aOR 1.50 (1.21-1.90)], and having HIV infection but not on ART [aOR 1.68 (1.23-2.32)]. Treatment initiation was substantially less likely for individuals testing negative with Xpert [aOR 0.77 (0.62-0.96)] compared to smear microscopy and declined in more recent years. Interpretation: Multiple factors influenced decisions to initiate TB treatment despite negative test results. Clinicians were substantially less likely to treat in the absence of a positive test result when using more sensitive, PCR-based diagnostics.

Identifiers

PMID38645191
PMCPMC11030305
OpenAlexW4394567506

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.